Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $263.83 million. The enterprise value is $294.70 million.
Important Dates
The next estimated earnings date is Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 72.33 million shares outstanding. The number of shares has increased by 41.82% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 72.33M |
| Shares Change (YoY) | +41.82% |
| Shares Change (QoQ) | -1.25% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 11.19% |
| Float | 41.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.16 |
| Forward PS | 9.03 |
| PB Ratio | 2.72 |
| P/TBV Ratio | 2.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.94.
| Current Ratio | 1.38 |
| Quick Ratio | 0.53 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.80 |
Financial Efficiency
Return on equity (ROE) is -48.02% and return on invested capital (ROIC) is -13.26%.
| Return on Equity (ROE) | -48.02% |
| Return on Assets (ROA) | -7.43% |
| Return on Invested Capital (ROIC) | -13.26% |
| Return on Capital Employed (ROCE) | -24.24% |
| Revenue Per Employee | $285,757 |
| Profits Per Employee | -$265,752 |
| Employee Count | 222 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cellectis has paid $455,000 in taxes.
| Income Tax | 455,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.16% in the last 52 weeks. The beta is 3.07, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 3.07 |
| 52-Week Price Change | +95.16% |
| 50-Day Moving Average | 3.29 |
| 200-Day Moving Average | 2.04 |
| Relative Strength Index (RSI) | 50.02 |
| Average Volume (20 Days) | 194,348 |
Short Selling Information
| Short Interest | 273,047 |
| Short Previous Month | 301,141 |
| Short % of Shares Out | 0.52% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.69 |
Income Statement
In the last 12 months, Cellectis had revenue of $63.44 million and -$59.00 million in losses. Loss per share was -$0.60.
| Revenue | 63.44M |
| Gross Profit | 63.44M |
| Operating Income | -45.22M |
| Pretax Income | -58.54M |
| Net Income | -59.00M |
| EBITDA | -33.04M |
| EBIT | -45.22M |
| Loss Per Share | -$0.60 |
Full Income StatementBalance Sheet
The company has $59.81 million in cash and $90.97 million in debt, giving a net cash position of -$31.16 million or -$0.43 per share.
| Cash & Cash Equivalents | 59.81M |
| Total Debt | 90.97M |
| Net Cash | -31.16M |
| Net Cash Per Share | -$0.43 |
| Equity (Book Value) | 97.11M |
| Book Value Per Share | 1.34 |
| Working Capital | 63.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.35 million and capital expenditures -$2.03 million, giving a free cash flow of -$35.37 million.
| Operating Cash Flow | -33.35M |
| Capital Expenditures | -2.03M |
| Free Cash Flow | -35.37M |
| FCF Per Share | -$0.49 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -71.28% and -93.00%.
| Gross Margin | 100.00% |
| Operating Margin | -71.28% |
| Pretax Margin | -92.28% |
| Profit Margin | -93.00% |
| EBITDA Margin | -52.08% |
| EBIT Margin | -71.28% |
| FCF Margin | n/a |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.82% |
| Shareholder Yield | -41.82% |
| Earnings Yield | -22.36% |
| FCF Yield | -13.41% |
Analyst Forecast
The average price target for Cellectis is $8.00, which is 120.39% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 120.39% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 26.84% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -0.95 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.95 |
| Piotroski F-Score | 3 |
